Read by QxMD icon Read

Hematological Oncology | Page 2

Juliana Cordeiro de Sousa, Mayumi da Nóbrega Ito, Marilia Braga Costa, Izabelle Rocha Farias, Daniela de Paula Borges, Roberta Taiane de Oliveira, Kiyoshi Ferreira Fukutani, Carolina Hassibe Thomé, Camila Maria da Silva Martinelli, Fabio Myajima, Daniel Onofre Vidal, Silvia Maria Meira Magalhães, Lorena Lobo Figueiredo-Pontes, Ronald Feitosa Pinheiro
No abstract text is available yet for this article.
March 28, 2019: Hematological Oncology
Hasan Abuamsha, Amer N Kadri, Adrian V Hernandez
Survival rates of patients with non-Hodgkin lymphoma (NHL) have improved over the last decade. However, cardiotoxicities remain important adverse consequences of treatment with chemotherapy and radiation, although the burden of cardiovascular mortality (CVM) in such patients remains unknown. We conducted a retrospective cohort study of patients greater than or equal to 20 years of age diagnosed with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) between 2000 and 2013 using data extracted from the United States Surveillance, Epidemiology, and End Results (SEER) database...
March 27, 2019: Hematological Oncology
Giovanni Caocci, Olga Mulas, Elisabetta Abruzzese, Luigiana Luciano, Alessandra Iurlo, Immacolata Attolico, Fausto Castagnetti, Sara Galimberti, Nicola Sgherza, Massimiliano Bonifacio, Mario Annunziata, Antonella Gozzini, Ester Maria Orlandi, Fabio Stagno, Gianni Binotto, Patrizia Pregno, Claudio Fozza, Malgorzata Monika Trawinska, Fiorenza De Gregorio, Daniele Cattaneo, Francesco Albano, Gabriele Gugliotta, Claudia Baratè, Luigi Scaffidi, Chiara Elena, Francesca Pirillo, Emilia Scalzulli, Giorgio La Nasa, Robin Foà, Massimo Breccia
Arterial occlusive events (AOEs) represent emerging complications in chronic myeloid leukemia (CML) patients treated with ponatinib. We identified 85 consecutive CML adult patients who were treated with ponatinib in 17 Italian centers. Patients were stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels. The 60-month cumulative incidence rate of AOEs excluding hypertension was 25.7%. Hypertension was reported in 14...
March 20, 2019: Hematological Oncology
Giancarlo Fatobene, Camila da Cruz Gouveia Linardi, Frederico Moreira, Gabriela Matos Falcão Targueta, Fernanda Maria Santos, Rodrigo Dolphini Velasques, Vanderson Rocha, Valeria Buccheri
No abstract text is available yet for this article.
March 7, 2019: Hematological Oncology
Evgenii Shumilov, Johanna Flach, Raphael Joncourt, Naomi Porret, Gertrud Wiedemann, Anne Angelillo-Scherrer, Lorenz Trümper, Martin Fiedler, Barbara Jeker, Ursula Amstutz, Thomas Pabst, Ulrike Bacher
No abstract text is available yet for this article.
March 6, 2019: Hematological Oncology
M Méndez, M Torrente, M Sánchez-Beato, J González-Rincón, A Royuela, J Gómez-Codina, L de la Cruz-Merino, A Rueda, M Llanos, C Quero, D Rodríguez-Abreu, J Gumá, S Monsalvo, P Sabin, M Provencio
Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma (NHL) subtype. The histological transformation (HT) of FL is an event considered frequent in the natural history of this tumor. We studied the transformation rates, predictive factors and treatment characteristics that may impact in the survival of patients with FL and HT. A total of 1074 patients diagnosed with FL were prospectively enrolled from 1990 to 2016 in a Spanish registry. 64 HTs were recorded based on clinical criteria (55%) or histological confirmation (45%)...
March 6, 2019: Hematological Oncology
L Aresu, P Buracco, R De Maria, S Iussich, M Martano, E Morello, G Bettini, S Comazzi, F Riondato, L Marconato
No abstract text is available yet for this article.
March 5, 2019: Hematological Oncology
Nadia Withofs, Yves Beguin, François Cousin, Tino Tancredi, Paolo Simoni, Victoria Alvarez-Miezentseva, Bernard De Prijck, Kaoutar Hafraoui, Christophe Bonnet, Frédéric Baron, Roland Hustinx, Jo Caers
The detection rates of whole-body combined [18F]NaF/[18F]FDG PET/CT, CT alone, MRI and X-ray were prospectively studied in patients with treatment-requiring plasma cell disorders The detection rates of imaging techniques were compared and focal lesions were classified according to their anatomic location. Twenty-six out of 30 initially included patients were assessable. The number of focal lesions detected in newly diagnosed patients (n = 13) and in relapsed patients (n = 13) were 296 and 234, respectively...
February 28, 2019: Hematological Oncology
Federica Irene Grifoni, Mariarita Sciumè, Valerio Pravettoni, Fabio Massimo Ulivieri, Simona Muratori, Nicola Stefano Fracchiolla, Elena Tagliaferri, Umberto Gianelli, Anna Chiara Migliorini, Lilla Cro, Annalisa Pacilli, Francesco Mannelli, Luca Baldini
Systemic mastocytosis (SM) is a hematological malignancy characterized by extracutaneous infiltration by atypical mast cells. Together with indolent SM, aggressive SM, and mast cell leukemia, the World Health Organization (WHO) recognizes another major disease subgroup: SM with an associated hematological neoplasm, which is characterized by the presence of a concurrent neoplasm, more commonly, a chronic myelomonocytic leukemia. While KIT D816V is commonly regarded as the driver mutation, the clinical presentation of SM is extremely varied...
April 2019: Hematological Oncology
Yair Herishanu, Tamar Tadmor, Andrei Braester, Osnat Bairey, Ariel Aviv, Naomi Rahimi-Levene, Riva Fineman, Itai Levi, Mona Yuklea, Rosa Ruchlemer, Lev Shvidel, Aaron Polliack
Chronic lymphocytic leukemia (CLL) is a disease of elderly patients. The fludarabine, cyclophosphamide, and rituximab (FCR) regimen is considered the treatment of choice for young fit patients with CLL; however, this combination is toxic for older patients. At the time this study was first planned and initiated, there was no standard chemo-immunotherapy regimen regarded as standard therapy for the less fit elderly patient with CLL. Here, we conducted a single-arm, phase II trial to examine the efficacy and safety of lower-dose fludarabine and cyclophosphamide combined with a standard dose of rituximab (LD-FCR) in elderly patients with previously untreated CLL...
February 12, 2019: Hematological Oncology
José C Jaime-Pérez, José R Padilla-Medina, Lorena Salazar-Cavazos, Lucía T Fernández, David Gómez-Almaguer
No abstract text is available yet for this article.
February 11, 2019: Hematological Oncology
Federica Duregon, Stefano Gobbo, Valentina Bullo, Enrico Roma, Barbara Vendramin, Manuele Bergamo, Danilo Sales Bocalini, Andrea Di Blasio, Lucia Cugusi, Daniel Neunhaeuserer, Marco Bergamin, Andrea Ermolao
Therapy of hematological malignancies lasts for long periods implicating various complications. The chemotherapy induces fatigue and forces bed rest. These features strongly contribute to a general impairment of the physical efficiency. Oppositely, an increase of physical exercise can prevent or reduce this weakening. Few trials examined the efficacy of an exercise in onco-hematological inpatients, during their hospitalization. Therefore, this study aimed to determine the feasibility of an inter-hospital intervention and the beneficial role of a tailored exercise program in the maintenance of the physical function in onco-hematological inpatients...
February 8, 2019: Hematological Oncology
Rintaro Ohe, Hong-Xue Meng, Naing Ye Aung, Akane Yamada, Takanobu Kabasawa, Aya Utsunomiya, Nobuyuki Tamazawa, Yuka Tamura, Takumi Kitaoka, Toshio Hashimoto, Kenichi Shibata, Tomomi Toubai, Wataru Kimura, Kenichi Ishizawa, Mitsunori Yamakawa
Hormone therapy has been used for patients with estrogen receptor alpha (ERα)-positive breast cancers. Recently, some studies reported the expression of ERα on neoplastic cells from B cell lymphomas. However, there has been only one report of ERα expression on the follicular dendritic cells (FDCs) that structurally and functionally support the microenvironment of follicular lymphomas (FLs). The objective of this study was to investigate the frequency of ERα expression on FDCs in nonneoplastic reactive lymphoid tissues and to compare the frequency of ERα expression on FDCs in the axillary lymph nodes between patients with and without antiestrogen therapy and among patients with grades 1-3 of FL...
February 8, 2019: Hematological Oncology
Iuliana Vaxman, Hanna Bernstine, Geffen Kleinstern, Natav Hendin, Shai Shimony, Liran Domachevsky, Ronit Gurion, David Groshar, Pia Raanani, Anat Gafter-Gvili
We evaluated the role of 18-Fluoro-2-deoxy-D-glucose positron emission tomography ([18F] FDG-PET) with computed tomography (CT) (PET/CT) as a diagnostic and prognostic tool in newly diagnosed marginal zone lymphoma (MZL) patients. This is a retrospective cohort study of patients with newly diagnosed MZL, treated with immunotherapy, chemotherapy regimens, surgery or helicobacter pylori eradication between 2008 and 2016 in a single tertiary center. Only patients who had a pre-treatment PET/CT (P-PET/CT) were included...
February 8, 2019: Hematological Oncology
Sara Rattotti, Virginia Valeria Ferretti, Chiara Rusconi, Andrea Rossi, Stefano Fogazzi, Luca Baldini, Pietro Pioltelli, Monica Balzarotti, Lucia Farina, Andrés J M Ferreri, Daniele Laszlo, Valentina Speziale, Marzia Varettoni, Roberta Sciarra, Lucia Morello, Alessandra Tedeschi, Marco Frigeni, Irene Defrancesco, Caterina Zerbi, Elena Flospergher, Maria Elena Nizzoli, Enrica Morra, Luca Arcaini
Chronic hepatitis C virus (HCV) infection is related with an increased risk of non-Hodgkin lymphomas (NHL). In indolent subtypes, regression of NHL was reported after HCV eradication with antiviral therapy (AT). In 2008 in Lombardy, a region of Northern Italy, the "Rete Ematologica Lombarda" (REL, Hematology Network of Lombardy-Lymphoma Workgroup) started a prospective multicenter observational cohort study on NHL associated with HCV infection, named "Registro Lombardo dei Linfomi HCV-positivi" ("Lombardy Registry of HCV-associated non-Hodgkin lymphomas")...
February 6, 2019: Hematological Oncology
(no author information available yet)
No abstract text is available yet for this article.
February 2019: Hematological Oncology
Alon Rozental, Anat Gafter-Gvili, Liat Vidal, Pia Raanani, Ronit Gurion
Randomized trials of maintenance therapy (MT) in diffuse large B cell lymphoma (DLBCL) are inconclusive regarding its effect on overall survival (OS) and disease control. We aimed to examine the efficacy and safety of MT in this meta-analysis. Systematic review and meta-analysis of randomized controlled trials comparing MT with observation or placebo, in patients with DLBCL, who achieved complete response (CR) or partial response (PR) after first-line chemotherapy with or without rituximab. Primary outcome was OS...
February 2019: Hematological Oncology
Camila Peña, Moises Russo, Virginia Martinez, Maria Elena Cabrera
The aim of the study was to describe the clinical and epidemiological characteristics, anatomic and histologic distribution, and treatment results of extranodal lymphomas (ENLs), diagnosed and treated in the public health system in Chile. We included patients with ENL diagnosed from 1998 to 2014, in 17 cancer centers, registered prospectively in the database of the National Adult Cancer Program (PANDA) of the Ministry of Health. Treatment was based on the local protocols for each lymphoma subtype. Extranodal lymphoma was documented in 1215 of 4907 non-Hodgkin lymphomas diagnosed in that period (25%)...
February 2019: Hematological Oncology
Ayumu Kubota, Nobuaki Nakano, Masahito Tokunaga, Takayoshi Miyazono, Mayumi Tokunaga, Torahiko Makino, Shogo Takeuchi, Kentaro Yonekura, Yoshifusa Takatsuka, Atae Utsunomiya
No abstract text is available yet for this article.
January 17, 2019: Hematological Oncology
Laura Nanni, Alice Morigi, Beatrice Casadei, Alessandro Broccoli, Vittorio Stefoni, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
No abstract text is available yet for this article.
January 13, 2019: Hematological Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"